2R-aminomethyl-6S-methyl-3R,4R,5R-trihydroxy tetrahydropyrane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2R-aminomethyl-6S-methyl-3R,4R,5R-trihydroxy tetrahydropyrane
• 英文别名: (2R,3R,4R,5R,6S)-2-(aminomethyl)-6-methyloxane-3,4,5-triol
• 化学式: C₇H₁₅NO₄
• 分子量: 177.2
• InChiKey: SKJSCJNAKNLIKB-MLKOFDEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  95.9
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2R-aminomethyl-6S-methyl-3R,4R,5R-trihydroxy tetrahydropyrane 、 肉桂酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 以33%的产率得到N-((6S)-methyl-(3R,4R,5R)-trihydroxytetrahydropyranosyl-(2R)-methyl)cinnamide
  参考文献：
  名称：

  Glycomimetics as pseudomonas Aeruginosa lectin inhibitors

  摘要：

  公开号：

  EP2650289B1

文献信息

• [EN] GLYCOMIMETICS AS PSEUDOMONAS AERUGINOSA LECTIN INHIBITORS<br/>[FR] GLYCOMIMÉTIQUES À TITRE D'INHIBITEURS DE LECTINE DE PSEUDOMONAS AERUGINOSA
  申请人：UNIV KONSTANZ

  公开号：WO2013152848A1

  公开（公告）日：2013-10-17

  The present invention relates to fucose- and mannose-derived glycomimetics and their general use in prophylaxis or treatment of Pseudomonas aeruginosa infections including respiratory tract infections, urinary tract infections, nosocomial infections and chronic wound infections in a patient encompassing a patient suffering already from cystic fibrosis. Said glycomimetics are inhibitors of Pseudomonas aeruginosa lectin LecB.

  本发明涉及与藻糖和甘露糖衍生的糖类类似物及其在预防或治疗包括呼吸道感染、尿道感染、医院感染和慢性伤口感染在内的假单胞菌感染中的一般用途，涉及患有囊性纤维化的患者。所述的糖类类似物是假单胞菌凝集素LecB的抑制剂。
• ANTIBODY-DRUG CONJUGATE (ADC) AND METHOD FOR FORMING THE SAME
  申请人：Industrial Technology Research Institute

  公开号：US20170119902A1

  公开（公告）日：2017-05-04

  An antibody-drug conjugate (ADC) of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), p is an integer ranging from 1 to 26, A is an antibody, and -(L-D) is a linker-drug unit. L is a linker unit having a glycopeptide, and D is a drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. A method for forming an antibody-drug conjugate (ADC) is also provided. A-(L-D) p (I)

  提供了公式（I）的抗体药物结合物（ADC）或其药学上可接受的盐或溶剂。在公式（I）中，p是1到26的整数，A是抗体，而-（L-D）是连接-药物单元。L是具有糖肽的连接单元，D是药物单元。通过抗体的半胱氨酸残基将抗体与连接单元结合。还提供了一种形成抗体药物结合物（ADC）的方法。A-（L-D）p（I）
• Glycomimetics As Pseudomonas Aeruginosa Lectin Inhibitors
  申请人：Universität Konstanz

  公开号：US20150361122A1

  公开（公告）日：2015-12-17

  The present invention relates to fucose- and mannose-derived glycomimetics and their general use in prophylaxis or treatment of Pseudomonas aeruginosa infections including respiratory tract infections, urinary tract infections, nosocomial infections and chronic wound infections in a patient encompassing a patient suffering already from cystic fibrosis. Said glycomimetics are inhibitors of Pseudomonas aeruginosa lectin LecB.
• COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES
  申请人：Industrial Technology Research Institute

  公开号：US20180016300A1

  公开（公告）日：2018-01-18

  A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), R1, R2 and R3 are each, independently, hydrogen, amino, nitro, halogen, hydroxyl, C1-C6 alkoxy, carboxylic acid, C1-C6 alkoxycarbonyl, C1-C6 amino, C1-C6 aminocarbonyl, C1-C6 alkyl, branched C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 heterocyclic, aryl or heteroaryl, provided at least one of R1 and R3 is an amino group. A linker-drug and a ligand-drug conjugate including the compound are also provided.
• US9371351B2
  申请人：——

  公开号：US9371351B2

  公开（公告）日：2016-06-21